As noted in my reply to Peter, I think the main advantage relative to the existing TNF-a biologics may be in lower COGS.
Yeah price is the biggie I left out, although I assume there won't be much, if any, advantage on this front for Ablynx's drug compared to the oral offerings to come, let alone the generic biologics on down the road.
Market Data 
Markets 
AI
